2015 Medicinal Chemistry Reviews

Volume 50
Manoj C. Desai, Editor-In-Chief

Medicinal Chemistry Reviews is an outstanding 600 page volume providing timely and critical reviews of important topics in medicinal chemistry. It is provided free of charge to MEDI members in electronic format. Members can also order a print copy, for the cost of printing, shipping and handling (US, $30; International, $50).   

Members:  To access your copy:

--Click 'Member Login' in the upper right corner of this page
--On the Member Login page, click the 'Resources' tab.

Nonmembers wishing to purchase a copy may click here and purchase at the non-member price.

Libraries and institutions interested in purchasing a copy should contact the Division Secretary, secretary@acsmedchem.org.

Table of Contents:

Introduction A History of Annual Reports in Medicinal Chemistry Volumes 1-49
Chapter 1 Science, Art, and Drug Discovery:  A Personal Perspective
Chapter 2

Some Thoughts On The Past 50 Years of Central Nervous System Therapeutic Research

Chapter 3

Recent Advances on the Inhibition of Endocannabinoid Hydrolysis

Chapter 4

Cardiovascular and Metabolic Diseases:  50 Years of Progress

Chapter 5

Recent Developments in HIF Prolyl Hydroxylase Inhibitors

Chapter 6

Efficacious Anti-Inflammatory and Respiratory Drugs:  Developments from 1965 to 2014

Chapter 7

PDE4 Inhibitors for the Treatment of Immune-Mediated and Inflammatory Diseases

Chapter 8

Progress into the Era of Genomically Targeted Cancer Drugs:  50 Years of Anticancer Medicinal Chemistry

Chapter 9

Targeting the B-cell Receptor Pathway in Hematological Malignancies

Chapter 10

Anti-infective Drugs Through Medicinal Chemistry:  A 50-year Retrospective

Chapter 11

Targeting the Number Two Infectious Disease Killer--Tuberculosis

Chapter 12

Fifty-five Years of Structural Biology:  A Perspective on How Biophysics Has Influenced Medicinal Chemistry

Chapter 13

Tackling Neurodegeneration with Multi-Target and Theranostic Small Molecules

Chapter 14

The Practice of Medicinal Chemistry and tis Contributions to Therapy

Chapter 15

Sofosbuvir:  A Breakthrough Curative Therapy for the Treatment of HCV Infection

Chapter 16

Case History:  Belsomra® (Suvorexant), A First-in-class Dual Orexin Receptor Antagonist for the Treatment of Insomnia

Chapter 17

Case History:  Brintellix® (Vortioxetine, Lu AA21004), an Antidepressant with Multimodal Activity

Chapter 18

New Chemical Entities Entering Phase III Trials in 2014

Chapter 19

To Market, To Market--2014

Volume 50 Web Addendum:  History of 3 Blockbuster Drugs

Dr. Patrick Woster, Medical University of South Carolina, has written a web addendum to his Introduction to Volume 50.  This addendum highlights the history of 3 blockbuster drugs as reported in Annual Reports.  You can view this addendum here.

ACS Division of Medicinal Chemistry

Webmaster:  secretary@acsmedchem.org